• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 3: New insider Flynn James E claimed ownership of 2,480,199 units of Class A Ordinary Shares

    11/14/22 6:12:52 PM ET
    $FLAC
    Business Services
    Finance
    Get the next $FLAC alert in real time by email
    SEC FORM 3 SEC Form 3
    FORM 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0104
    Estimated average burden
    hours per response: 0.5
    1. Name and Address of Reporting Person*
    Flynn James E

    (Last) (First) (Middle)
    345 PARK AVENUE SOUTH, 12TH FLOOR

    (Street)
    NEW YORK NY 10010

    (City) (State) (Zip)
    2. Date of Event Requiring Statement (Month/Day/Year)
    11/08/2022
    3. Issuer Name and Ticker or Trading Symbol
    Frazier Lifesciences Acquisition Corp [ FLAC ]
    4. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    Director X 10% Owner
    Officer (give title below) X Other (specify below)
    Possible Member of 10% Group
    5. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    Form filed by One Reporting Person
    X Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Beneficially Owned
    1. Title of Security (Instr. 4) 2. Amount of Securities Beneficially Owned (Instr. 4) 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 4. Nature of Indirect Beneficial Ownership (Instr. 5)
    Class A Ordinary Shares 2,480,199 I Through Deerfield Partners, L.P.(1)(2)
    Table II - Derivative Securities Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 4) 2. Date Exercisable and Expiration Date (Month/Day/Year) 3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) 4. Conversion or Exercise Price of Derivative Security 5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 6. Nature of Indirect Beneficial Ownership (Instr. 5)
    Date Exercisable Expiration Date Title Amount or Number of Shares
    Warrants(3) (3) (3) Class A Ordinary Shares 92,787 11.5(3) I Through Deerfield Partners, L.P.(1)(2)
    1. Name and Address of Reporting Person*
    Flynn James E

    (Last) (First) (Middle)
    345 PARK AVENUE SOUTH, 12TH FLOOR

    (Street)
    NEW YORK NY 10010

    (City) (State) (Zip)
    1. Name and Address of Reporting Person*
    Deerfield Mgmt L.P.

    (Last) (First) (Middle)
    345 PARK AVENUE SOUTH, 12TH FLOOR

    (Street)
    NEW YORK NY 10010

    (City) (State) (Zip)
    1. Name and Address of Reporting Person*
    DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C)

    (Last) (First) (Middle)
    345 PARK AVENUE SOUTH, 12TH FLOOR

    (Street)
    NEW YORK NY 10010

    (City) (State) (Zip)
    1. Name and Address of Reporting Person*
    DEERFIELD PARTNERS, L.P.

    (Last) (First) (Middle)
    345 PARK AVENUE SOUTH, 12TH FLOOR

    (Street)
    NEW YORK NY 10010

    (City) (State) (Zip)
    Explanation of Responses:
    1. This Form 3 is being filed by the undersigned as well as the entities listed on the Joint Filer Information Statement attached as an exhibit hereto (the "Reporting Persons"). Deerfield Mgmt, L.P. is the general partner of Deerfield Partners, L.P. (the "Fund"). Deerfield Management Company, L.P. is the investment manager of the Fund. James E. Flynn is the sole member of the general partner of each of Deerfield Mgmt, L.P. and Deerfield Management Company, L.P.
    2. In accordance with Instruction 5 (b)(iv) to Form 3, the entire amount of the Issuer's securities held by the Fund is reported herein. For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its indirect pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise.
    3. The warrants may be exercised only during the period commencing on the date that is thirty days after the date on which the Issuer completes its initial business combination and ending on the earlier to occur of the five year anniversary of the date on which the Issuer consummates its initial business combination and the date that the warrants are redeemed. The Exercise Price is subject to adjustment as provided in the warrants.
    Remarks:
    Please see Joint Filer Information Statement attached as Exhibit 99 hereto. Jonathan Isler, Attorney-in-Fact: Power of Attorney, which is hereby incorporated by reference to Exhibit 24 to a Form 4 with regard to DA32 Life Science Tech Acquisition Corp. filed with the Securities and Exchange Commission on August 3, 2021 by Deerfield Partners, L.P., Deerfield Mgmt, L.P., Deerfield Management Company, L.P. and James E. Flynn.
    /s/ Jonathan Isler, Attorney-in-Fact 11/14/2022
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $FLAC alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $FLAC

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $FLAC
    SEC Filings

    See more
    • SEC Form 15-12G filed by Frazier Lifesciences Acquisition Corporation

      15-12G - Frazier Lifesciences Acquisition Corp (0001828326) (Filer)

      12/2/22 4:30:53 PM ET
      $FLAC
      Business Services
      Finance
    • Frazier Lifesciences Acquisition Corporation filed SEC Form 8-K: Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Material Modification to Rights of Security Holders, Changes in Control of Registrant, Leadership Update, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - Frazier Lifesciences Acquisition Corp (0001828326) (Filer)

      11/23/22 4:36:01 PM ET
      $FLAC
      Business Services
      Finance
    • SEC Form 25-NSE filed by Frazier Lifesciences Acquisition Corporation

      25-NSE - Frazier Lifesciences Acquisition Corp (0001828326) (Subject)

      11/22/22 4:17:19 PM ET
      $FLAC
      Business Services
      Finance

    $FLAC
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Frazier Lifesciences Acquisition Corporation (Amendment)

      SC 13G/A - Frazier Lifesciences Acquisition Corp (0001828326) (Subject)

      2/15/23 10:14:02 AM ET
      $FLAC
      Business Services
      Finance
    • SEC Form SC 13G/A filed by Frazier Lifesciences Acquisition Corporation (Amendment)

      SC 13G/A - Frazier Lifesciences Acquisition Corp (0001828326) (Subject)

      12/1/22 4:51:17 PM ET
      $FLAC
      Business Services
      Finance
    • SEC Form SC 13D/A filed by Frazier Lifesciences Acquisition Corporation (Amendment)

      SC 13D/A - Frazier Lifesciences Acquisition Corp (0001828326) (Subject)

      11/25/22 1:43:14 PM ET
      $FLAC
      Business Services
      Finance

    $FLAC
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Phathom Pharmaceuticals Appoints Dr. James Topper to its Board of Directors

      FLORHAM PARK, N.J., Sept. 26, 2022 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases and disorders, today announced the appointment of James "Jamie" Topper, M.D., Ph.D., to its Board of Directors. Dr. Topper currently serves as a Managing Partner at Frazier Life Sciences, which invests globally in private and publicly traded companies that discover, develop, and commercialize innovative biopharmaceuticals. He is also the Chairman and Chief Executive Officer of Frazier Lifesciences Acquisition Corporation (NASDAQ:FLAC). In addition to those leadership roles, he

      9/26/22 8:00:00 AM ET
      $ALPN
      $ANAB
      $FLAC
      $PHAT
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Business Services
      Finance
    • Frazier Healthcare Partners Announces Several Promotions on Life Sciences Team

      Frazier Healthcare Partners announced today the promotion of four Life Sciences team members: Jamie Brush, M.D., to General Partner and Portfolio Manager, David Topper to Partner, Capital Markets, Liz Park to Principal, Investor Relations, and Joe Cabral to Senior Associate. Dr. Brush joined the Frazier Life Sciences team in 2016 and co-leads Frazier's public equity investment strategy. He is the co-portfolio manager for Frazier Life Sciences Public Fund, an $830 million long-only fund that invests in small- and mid-cap public biotech companies. He led Frazier's public investments in Trillium Therapeutics (NASDAQ:TRIL, pending acquisition by Pfizer))), Translate Bio (NASDAQ:TBIO, acquired

      10/28/21 8:00:00 AM ET
      $FLAC
      $ISEE
      $KRYS
      $RCKT
      Business Services
      Finance
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $FLAC
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Viking Global Investors Lp

      4 - Frazier Lifesciences Acquisition Corp (0001828326) (Issuer)

      11/25/22 1:35:02 PM ET
      $FLAC
      Business Services
      Finance
    • SEC Form 4 filed by Topper David Joseph

      4 - Frazier Lifesciences Acquisition Corp (0001828326) (Issuer)

      11/23/22 4:31:11 PM ET
      $FLAC
      Business Services
      Finance
    • SEC Form 4 filed by Bigham Michael

      4 - Frazier Lifesciences Acquisition Corp (0001828326) (Issuer)

      11/23/22 4:27:56 PM ET
      $FLAC
      Business Services
      Finance

    $FLAC
    Leadership Updates

    Live Leadership Updates

    See more
    • Phathom Pharmaceuticals Appoints Dr. James Topper to its Board of Directors

      FLORHAM PARK, N.J., Sept. 26, 2022 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases and disorders, today announced the appointment of James "Jamie" Topper, M.D., Ph.D., to its Board of Directors. Dr. Topper currently serves as a Managing Partner at Frazier Life Sciences, which invests globally in private and publicly traded companies that discover, develop, and commercialize innovative biopharmaceuticals. He is also the Chairman and Chief Executive Officer of Frazier Lifesciences Acquisition Corporation (NASDAQ:FLAC). In addition to those leadership roles, he

      9/26/22 8:00:00 AM ET
      $ALPN
      $ANAB
      $FLAC
      $PHAT
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Business Services
      Finance